Email: cspc@cspc.cn
News
News Center
Nov. 12
2024
BIVALENT HPV mRNA THERAPEUTIC VACCINE (SYS6026)OBTAINS CLINICAL TRIAL APPROVAL
Oct. 25
VOLUNTARY ANNOUNCEMENT FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS FURTHER CLINICAL TRIAL APPROVAL FOR NEW INDICATION
Oct. 08
VOLUNTARY ANNOUNCEMENT CPO301 RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
VOLUNTARY ANNOUNCEMENT OMALIZUMAB FOR INJECTION OBTAINS MARKETING APPROVAL GRANTED BY NMPA
Oct. 07
VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR YS2302018 WITH ASTRAZENECA
Sep. 30
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH JIANGSU ALPHAMAB FOR THE DEVELOPMENT AND COMMERCIALIZATION OF JSKN003 IN MAINLAND CHINA
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
